Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR Platform

June 28, 2023

We can profile the patient, find out what they need, we pull the appropriate targeting ligand from the freezer, couple it to the cell we pulled from the freezer, and by the end of that day, they are being treated with a customized therapy for their cancer. But the beauty of the system goes beyond that – in addition to the fact that we can treat them specifically for their tumor cells, we can follow them. This is a feedback loop, so once we find out that we’ve killed all the cancer cells that express those 2 targets, but a small population of cells is starting to grow that are expressing a third targetwe didn’t administer, all we have to do is take that SpyTagligand from the freezer and infuse it into the patient. The cells are there, they’re ready to be rearmed. And we believe that we can cure this patient.

Related Post

×